Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2061-2080 of 3,900 trials

Irritable Bowel Syndrome: Symbioflor®2 Treatment

We are studying an oral treatment with living bacteria for people with diarrhea-predominant irritable bowel syndrome (IBS-D). The goal is to see if it helps reduce symptoms compared to a placebo.

Irritable Bowel Syndrome6-12 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementGastroenterology

Pain Management After Colorectal Surgery: Continuous Wound Infusion Study

We are investigating whether continuous infusion of local pain relief helps patients recover better after minimally invasive colorectal surgery. The study compares this method to a placebo to see its effects on pain and recovery time.

Recovery After Colorectal Surgery1-2 yearsConfirmation phase (III)Standard MedicinesGastroenterologyInternal MedicineOtolaryngology

Brain Surgery Pain Management: Nerve Block Comparison

We are comparing two types of nerve blocks to see which one helps reduce pain and improve recovery for patients undergoing brain surgery. This study aims to find the best option for managing discomfort during the procedure.

Patients Undergoing Craniotomy for Supratentorial Mass>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Severe Asthma: Tezepelumab Medication Study

We are studying if tezepelumab can help patients aged 12 to 80 with severe asthma reduce their daily medication while keeping their symptoms under control.

Severe Asthma1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePulmonology

Diffuse Large B-Cell Lymphoma: Selinexor Study

We are testing the drug Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma. This study aims to explore its potential effectiveness in treating this challenging condition.

Relapsed/Refractory Diffuse Large B-Cell LymphomaEfficacy phase (II)HematologyOncology

Colorectal Cancer: Encorafenib and Cetuximab with Pembrolizumab

We are studying a combination of medications for patients with BRAF V600E-mutant metastatic colorectal cancer. The goal is to see if this combination works better than pembrolizumab alone.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Generalized Myasthenia Gravis: Telitacicept Study

We are testing a new treatment called telitacicept for people with generalized myasthenia gravis. The study aims to see if it works better than a placebo and to check its safety.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurologyRheumatology

Pancreatic Cancer: Digitoxin and Chemotherapy Study

We are exploring whether adding digitoxin to chemotherapy can help improve survival for patients with inoperable pancreatic cancer. The trial also looks at treatment safety and quality of life.

Pancreatic Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Prostate Cancer: Darolutamide Addition Study

We are studying whether adding darolutamide to standard treatment helps men with metastatic castration-resistant prostate cancer live longer without cancer progression.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Multiple Myeloma: Etentamig and Iberdomide Study

We are investigating the safety and effects of a new treatment combining etentamig and iberdomide for patients with relapsed or refractory multiple myeloma. This study aims to find the best doses and assess how well the treatment works.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Breast Cancer: New Eye Safety Drug Study

We are investigating the safety of a new drug for breast cancer patients, specifically looking at its effects on eye health. This study aims to ensure that the treatment does not harm vision.

Breast Cancer>2 yearsSafety phase (I)OncologyOphthalmology

GLM101 for PMM2-CDG: Safety and Effects

We are studying the safety of GLM101 in patients with PMM2-CDG who have previously received the treatment. We will also look at its impact on coordination, balance, and sugar levels.

PMM2-CDGEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal Medicine

Cognitive and Motor Function Study: Donepezil in Older Adults

We are investigating whether a medication can improve thinking and movement tasks in elderly volunteers. This study compares the effects of donepezil to a placebo on brain activity and performance.

Neurological Disorders≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementNeurology

Advanced Non-Small Cell Lung Cancer: PD-1 Inhibitor with Chemotherapy and Radiation

We are studying whether adding radiation to a PD-1 inhibitor and chemotherapy improves survival and tumor response in patients with advanced non-small cell lung cancer. This trial also looks at side effects and quality of life.

Advanced Non-Small Cell Lung Cancer (NSCLC)3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Metastatic Colorectal Cancer: Post-Surgery Chemotherapy Study

We are investigating whether adding chemotherapy after surgery or ablation helps improve outcomes for patients with metastatic colorectal cancer compared to just follow-up care.

Metastatic Colorectal CancerConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Solid Cancers: NILK-2401 Antibody Study

We are testing a new antibody treatment for solid cancers, both alone and with another cancer therapy. This study aims to find out how effective it may be for patients.

Advanced Solid Tumor>2 yearsSafety phase (I)Oncology

Bladder Cancer: Nadofaragene Firadenovec Treatment

We are studying the safety and effectiveness of nadofaragene firadenovec, given alone or with chemotherapy or immunotherapy, for adults with non-muscle invasive bladder cancer that hasn't responded to BCG therapy.

High-risk Non-Muscle-Invasive Bladder Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Kidney Health: SGLT2 Inhibitor for Prediabetes

We are studying whether adding a new medication to lifestyle changes can help improve kidney function in people with prediabetes. This trial will help us understand its potential benefits for kidney health.

Early Stage Chronic Kidney Disease6-12 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesEndocrinologyNephrology

Fluid Overload in ICU: Furosemide Treatment

We are studying whether a diuretic called furosemide helps critically ill patients with fluid overload recover better than a placebo. The focus is on increasing the number of days alive and out of the hospital after 90 days.

Fluid Overload>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

Burn Treatment in Children: New Skin Graft Study

We are testing a new skin graft made from the child's own cells for treating severe burns in children. The goal is to see if it works better and is safer than the standard skin graft method.

Children with Severe Burns1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatology